Chimeric antigen receptor (CAR) T-cell therapy is a groundbreaking approach for treating certain hematologic malignancies and solid tumors. However, its application is limited by severe toxicities, particularly cytokine release syndrome (CRS) and cell-associated neurotoxicity syndrome (ICANS), dramatically limit its broader application. IL-1 plays a crucial role in both enhancing CAR T-cell efficacy and driving these toxic effects. This review systematically examines the dual functions of IL-1, highlighting its role in promoting CAR T-cell activation and persistence while contributing to CRS and ICANS pathogenesis. Strategies to mitigate IL-1-driven toxicities, including IL-1 receptor antagonists, monoclonal antibodies, IL-1 trapping, and interference with IL-1 production, show promise in reducing adverse effects without compromising therapeutic efficacy. Understanding the complex role of IL-1 in CAR T-cell therapy may lead to optimized treatment strategies, improving safety and expanding clinical applicability. Further research is essential to refine IL-1-targeted interventions and enhance the therapeutic potential of CAR T-cell therapy.
Maali, A., Noei, A., Feghhi-Najafabadi, S. & Sharifzadeh, Z. (2024). A Systematic Review on the Dual Role of Interleukin-1 in CAR T-Cell Therapy: Enhancer and Mitigator. Iranian Biomedical Journal, 28(Issue 5 & 6), 221–234. https://doi.org/10.61186/ibj.4444
MLA
Maali, A., Noei, A., Feghhi-Najafabadi, S., & Sharifzadeh, Z. "A Systematic Review on the Dual Role of Interleukin-1 in CAR T-Cell Therapy: Enhancer and Mitigator", Iranian Biomedical Journal, 28, Issue 5 & 6, 2024, 221–234. doi: 10.61186/ibj.4444
HARVARD
Maali, A., Noei, A., Feghhi-Najafabadi, S., & Sharifzadeh, Z. (2024). 'A Systematic Review on the Dual Role of Interleukin-1 in CAR T-Cell Therapy: Enhancer and Mitigator', Iranian Biomedical Journal, 28(Issue 5 & 6), pp. 221–234. doi: 10.61186/ibj.4444
CHICAGO
Maali, A., Noei, A., Feghhi-Najafabadi, S. & Sharifzadeh, Z., "A Systematic Review on the Dual Role of Interleukin-1 in CAR T-Cell Therapy: Enhancer and Mitigator." Iranian Biomedical Journal, 28 Issue 5 & 6 (2024): 221–234, doi: 10.61186/ibj.4444
VANCOUVER
Maali A., Noei A., Feghhi-Najafabadi S., Sharifzadeh Z. A Systematic Review on the Dual Role of Interleukin-1 in CAR T-Cell Therapy: Enhancer and Mitigator. Iranian Biomedical Journal. 2024;28(Issue 5 & 6):221–234. doi: 10.61186/ibj.4444
